Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00294320 | Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions | PHASE3 | COMPLETED | 12 | — | — | Feb 1, 2006 | Jan 1, 2007 | Feb 7, 2022 | 1 | France |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 250mg of Imiquimod cream application once daily 3 times per week. |
| 2 | PLACEBO_COMPARATOR | 250mg vehicle cream for application once daily 3 times per week. |
| Name | Type | Description |
|---|---|---|
| Aldara (Imiquimod) | DRUG | 250mg of Imiquimod cream for application once daily 3 times per week. |
| Vehicle cream | OTHER | 250mg vehicle cream for application once daily 3 times per week. |
Inclusion Criteria: * At least 5 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions * Free of any significant findings (e.g tattoos) in the potential application site area. * Willing to discontinue sun-tanning and use of sunbed/sun parlour use * Willing to stop use...